在第12周的性结肠炎患者活检中,Mirikizumab诱导的转录组变化维持到第52周
Travis Johnson1, Boyd Steere2, Pengyue Zhang1
1Indiana Clinical and Translational Sciences Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Clinical and translational gastroenterology
|August 18, 2023
概括
在性结肠炎 (UC) 患者的Mirikizumab治疗导致持续的基因表达变化,表明分子愈合途径. 这些变化与疾病活性降低相关,这表明对干白素-23抑制有明显的反应.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 作为抗联素-23p19抗体的Mirikizumab已在中度至重度的性结肠炎 (UC) 中显示出有效性.
- 以前的研究表明,mirikizumab降低了与UC相关的转录和与TNF抑制剂耐药性相关的转录.
研究的目的:
- 评估在12周对mirikizumab反应的中度至重度UC患者的第52周基因表达变化.
- 确定与mirikizumab治疗相关的分子通路及其与疾病活性的相关性.
主要方法:
- 来自第二阶段AMAC研究 (NCT02589665) 的结肠粘膜活检的分析.
- 使用limma R包进行基因表达分析,从基线到第52周识别差异表达基因 (DEG) 和类似表达基因 (DEGSEG).
- 对DEGSEG集群与修改后的梅奥得分和罗巴特组织病理学指数的相关性分析.
主要成果:
- 与安慰剂反应者相比,Mirikizumab反应者表现出更广泛,更持续的转录变化.
- 显著的比例的DEGSEGs是独特的mirikizumab响应者,表明一个特定的分子治疗签名.
- DEGSEG集群与UC疾病活动的临床 (修改后的梅奥得分) 和组织病理学 (罗巴茨组织病理学指数) 测量相关.
结论:
- 在UC患者中,Mirikizumab治疗诱导了明显和持续的分子变化,表明了愈合途径.
- 这些分子变化与临床和内镜改善有关,突显了IL-23抑制在UC中的作用.
- 基因表达特征分析提供了对米里基祖马布机制的洞察力,并可以作为治疗反应的生物标志物.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
215
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
215